➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Afuresertib

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Afuresertib?

Afuresertib is an investigational drug.

There have been 10 clinical trials for Afuresertib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2015.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Prostatic Neoplasms. The leading clinical trial sponsors are GlaxoSmithKline, Laekna Limited, and Novartis Pharmaceuticals.

There are fifty-seven US patents protecting this investigational drug and four hundred and eighty-one international patents.

Recent Clinical Trials for Afuresertib
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast CancerLaekna LLCPhase 1
Study With Afuresertib and Paclitaxel in Platinum Resistant OvarianLaekna LimitedPhase 2
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPCLaekna LimitedPhase 1/Phase 2

See all Afuresertib clinical trials

Clinical Trial Summary for Afuresertib

Top disease conditions for Afuresertib
Top clinical trial sponsors for Afuresertib

See all Afuresertib clinical trials

US Patents for Afuresertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Afuresertib   Get Started Free Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)   Get Started Free
Afuresertib   Get Started Free .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA)   Get Started Free
Afuresertib   Get Started Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started Free
Afuresertib   Get Started Free Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population UNITY BIOTECHNOLOGY, INC. (Brisbane, CA) BUCK INSTITUE FOR RESEARCH ON AGING (Novato, CA) MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (Rochester, MN)   Get Started Free
Afuresertib   Get Started Free Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways Asana BioSciences, LLC (Lawrenceville, NJ)   Get Started Free
Afuresertib   Get Started Free Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof ZHEJIANG UNIVERSITY (Zhejiang, CN) SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (Shanghai, CN)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Afuresertib

Drugname Country Document Number Estimated Expiration Related US Patent
Afuresertib Australia AU2015211021 2034-01-28   Get Started Free
Afuresertib Australia AU2020244600 2034-01-28   Get Started Free
Afuresertib Brazil BR112016017564 2034-01-28   Get Started Free
Afuresertib Canada CA2939121 2034-01-28   Get Started Free
Afuresertib Canada CA3100140 2034-01-28   Get Started Free
Afuresertib China CN106163557 2034-01-28   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.